康恩貝(600572.SH):省國貿集團收購公司控股權獲浙江國資委批覆
格隆匯 6 月 23日丨康恩貝(600572.SH)公佈,2020年6月22日,省國貿集團收到浙江省國資委出具的《浙江省國資委關於同意收購浙江康恩貝製藥股份有限公司控股權的批覆》(浙國資產權[2020]19號),主要內容如下:
“根據《上市公司國有股權監督管理辦法》(國資委、財政部、證監會令第36號)及相關政策規定,經研究,現批覆如下:
一、原則同意你公司上報的收購浙江康恩貝製藥股份有限公司控股股權方案,浙江省中醫藥健康產業集團有限公司(為國有股東)協議受讓康恩貝集團有限公司所持浙江康恩貝製藥股份有限公司20%股份,合計533464040股。
二、你公司要嚴格控制收購風險,按照國家有關政策規定規範推進本次協議受讓股份工作,落實風險防控措施,切實維護國有股東權益。
三、你公司要加強對收購後企業的管理,探索優化企業治理管控,努力打造混合所有制改革樣板,實現公司高質量發展。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.